Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026 at 1:40 PM EDT. CEO Dr. Neal Walker and senior leaders will join a fireside chat. A live and archived webcast will be available on the company Events page for at least 30 days.

Key Figures

Conference date: March 10, 2026 Presentation time: 1:40 PM EDT Webcast availability: At least 30 days +5 more

8 metrics

Conference date March 10, 2026 Date of Leerink Partners 2026 Global Healthcare Conference fireside chat

Presentation time 1:40 PM EDT Scheduled time for Aclaris fireside chat

Webcast availability At least 30 days Duration the conference webcast will remain on company website

Price change 6.27% ACRS 24-hour price change prior to this news

Relative volume 3.57x Today’s volume vs. 20-day average before news

52-week range $1.05–$4.89 52-week low and high before this announcement

Price vs 52-week high -37.63% Distance from 52-week high prior to news

Price vs 52-week low 190.48% Gain from 52-week low prior to news

Market Reality Check

Price: $3.05 Vol: Volume 4,851,422 is 3.57x...

high vol

$3.05 Last Close

Volume Volume 4,851,422 is 3.57x the 20-day average of 1,359,588, indicating elevated interest into this conference update. high

Technical Price at $3.05 is trading above the 200-day moving average of $2.26 after this conference announcement.

Peers on Argus

Despite ACRS up 6.27%, momentum peers IMMP and SLN showed downside moves of abou...

2 Down

Despite ACRS up 6.27%, momentum peers IMMP and SLN showed downside moves of about -6.37% and -9.87% (median around -8.1%), indicating today’s strength in ACRS diverged from weaker sector momentum.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and update	Positive	-5.4%	Q4 and 2025 results plus pipeline/cash runway update drew a negative move.
Feb 24	Clinical trial start	Positive	+3.4%	Initiation of Phase 1b ATI-052 asthma POC trial prompted a modest gain.
Feb 04	Conference participation	Neutral	+2.0%	Announcements of February conference appearances coincided with a small price uptick.
Jan 27	Preclinical data	Positive	+1.3%	Strong murine hair-regrowth data for ATI-2138 supported a modest positive reaction.
Jan 12	Clinical trial start	Positive	+0.8%	Launch of Phase 1b ATI-052 trial in atopic dermatitis led to a slight gain.

Pattern Detected

Recent clinical and corporate updates have generally seen aligned, modestly positive price reactions, while the latest earnings/corporate update drew a negative response.

Recent Company History

Over the past few months, Aclaris has focused on advancing its immuno‑inflammatory pipeline, including ATI‑052 Phase 1b proof‑of‑concept trials in atopic dermatitis and asthma and preclinical hair‑regrowth data for ATI‑2138, with a planned Phase 2b trial in H1 2026. Conference participation in February 2026 drew small positive moves, while the Q4 and full‑year 2025 report on Feb 26, 2026 saw a -5.44% reaction despite highlighting cash of $151.4M and a runway into H2 2028. Today’s conference appearance continues that emphasis on visibility with investors.

Market Pulse Summary

This announcement highlights Aclaris management’s participation in a Leerink healthcare conference o...

Analysis

This announcement highlights Aclaris management’s participation in a Leerink healthcare conference on March 10, 2026, with a webcast available for at least 30 days. It follows recent clinical progress in ATI‑052 and ATI‑2138 and a Q4 2025 update outlining cash of $151.4M and runway into H2 2028. Investors may track how the company frames its immuno‑inflammatory pipeline, capital position, and upcoming milestones alongside prior earnings and trial initiations when reviewing the webcast.

AI-generated analysis. Not financial advice.

WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

When will Aclaris (ACRS) present at the Leerink Partners 2026 Global Healthcare Conference?

Aclaris will present on Tuesday, March 10, 2026 at 1:40 PM EDT in Miami. According to Aclaris, CEO Dr. Neal Walker and senior leaders will participate in a fireside chat during the conference to discuss company developments and strategy.

How can investors watch Aclaris (ACRS) at the March 10, 2026 Leerink conference?

Investors can watch a live webcast and archived video on the company Events page. According to Aclaris, the webcast will be accessible at www.aclaristx.com and will remain available for at least 30 days after the event.

Who from Aclaris (ACRS) will speak at the March 10, 2026 fireside chat?

Aclaris CEO Dr. Neal Walker and other senior leadership team members will speak at the fireside chat. According to Aclaris, the session features company executives discussing clinical-stage programs and corporate updates at the conference.

Will the Aclaris (ACRS) Leerink webcast be available after the March 10, 2026 event?

Yes, the webcast will be archived and available for at least 30 days on the Events page. According to Aclaris, both live and archived webcasts will be accessible via the company website for post-event viewing.

Where is the Leerink Partners 2026 Global Healthcare Conference taking place for Aclaris (ACRS)?

The conference is in Miami, Florida, and Aclaris will present on March 10, 2026 at 1:40 PM EDT. According to Aclaris, the company’s executives will join a scheduled fireside chat at that location and time.

What topics will Aclaris (ACRS) likely cover in the March 10, 2026 fireside chat?

The fireside chat will cover recent company developments and clinical-stage programs led by Aclaris senior leaders. According to Aclaris, executives will discuss strategy, program updates, and corporate outlook during the session at the conference.